A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours

被引：0
|
作者：
de Bono, J. S. [1 ]
Lord, S. [2 ]
Yap, C. [3 ]
Rowinsky, E. K. [4 ]
Gandhi, N. A. [4 ]
Thakkar, D. [5 ]
Ingram, P. J. [5 ]
Padmanabhan, N. [6 ]
Chandran, K. [7 ,8 ]
Paschalis, A. [9 ]
McGuigan, L. [10 ]
Neal, P. [10 ]
Paisley, D. [10 ]
Walter, H. S. [10 ]
Kelly, F. [10 ]
Craigan, J. [10 ]
Westwood, N. B. [10 ]
Halbert, G. [10 ]
Boyd-Kirkup, J. D. [11 ]
Halford, S. E. R. [10 ]
机构：
[1] ICR Inst Canc Res, London, England
[2] Univ Oxford, Oncol, Oxford, England
[3] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England
[4] Hummingbird Biosci, Dis Area Strategy, Houston, TX USA
[5] Hummingbird Biosci Pte Ltd, Pharmacol Dept, Temasek Lifesci Labs, Singapore, Singapore
[6] Hummingbird Biosci Pte Ltd, Pharmacol, Temasek Lifesci Labs, Singapore, Singapore
[7] Inst Canc Res, Med Oncol, Sutton, England
[8] Royal Marsden Hosp, Sutton, England
[9] ICR Inst Canc Res, Clin Studies, London, England
[10] CRUK Canc Res UK, Ctr Drug Dev, London, England
[11] Hummingbird Biosci Pte Ltd, Res, Temasek Lifesci Labs, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.621
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
493TiP
引用
收藏
页码：S767 / S767
页数：1
相关论文
共 50 条
  • [21] Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
    Metzger Filho, O.
    Leone, J. P.
    Li, T.
    Tan-Wasielewski, Z.
    Trippa, L.
    Barry, W. T.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R. A.
    Tolaney, S. M.
    Krop, I
    Winer, E. P.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1231 - 1239
  • [22] Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
    Jaenne, Pasi A.
    Boss, David S.
    Camidge, D. Ross
    Britten, Carolyn D.
    Engelman, Jeffrey A.
    Garon, Edward B.
    Guo, Feng
    Wong, Steven
    Liang, Jane
    Letrent, Stephen
    Millham, Robert
    Taylor, Ian
    Eckhardt, S. Gail
    Schellens, Jan H. M.
    CLINICAL CANCER RESEARCH, 2011, 17 (05) : 1131 - 1139
  • [23] Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    LoRusso, Patricia
    Jaenne, Pasi A.
    Oliveira, Moacyr
    Rizvi, Naiyer
    Malburg, Lisa
    Keedy, Vicki
    Yee, Lorrin
    Copigneaux, Catherine
    Hettmann, Thore
    Wu, Chi-Yuan
    Ang, Agnes
    Halim, Abdel-Baset
    Beckman, Robert A.
    Beaupre, Darrin
    Berlin, Jordan
    CLINICAL CANCER RESEARCH, 2013, 19 (11) : 3078 - 3087
  • [24] A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
    U Lassen
    D L Nielsen
    M Sørensen
    L Winstedt
    T Niskanen
    Y Stenberg
    S Pakola
    J-M Stassen
    S Glazer
    British Journal of Cancer, 2012, 106 : 678 - 684
  • [25] A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
    Lassen, U.
    Nielsen, D. L.
    Sorensen, M.
    Winstedt, L.
    Niskanen, T.
    Stenberg, Y.
    Pakola, S.
    Stassen, J-M
    Glazer, S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 678 - 684
  • [26] A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
    Gan, Hui K.
    Millward, Michael
    Jalving, Mathilde
    Garrido-Laguna, Ignacio
    Lickliter, Jason D.
    Schellens, Jan H. M.
    Lolkema, Martijn P.
    Van Herpen, Carla L. M.
    Hug, Bruce
    Tang, Lihua
    O'Connor-Semmes, Robin
    Gagnon, Robert
    Ellis, Catherine
    Ganji, Gopinath
    Matheny, Christopher
    Drilon, Alexander
    ONCOLOGIST, 2021, 26 (10): : E1844 - E1853
  • [27] Updated analysis of phase I dose-escalation and dose cohort expansion studies of senaparib (IMP4297) in Chinese patients with advanced solid tumours
    Xu, B.
    Junning, C.
    Guo, H.
    Zhang, P.
    Yang, S.
    Zhou, Y.
    Zhang, R.
    Dongmei, J.
    Shen, W.
    Zhang, S.
    Cai, S.
    Tian, Y. E.
    Hsieh, C-Y.
    Xu, C.
    Ma, N.
    Chen, Y.
    Yang, S.
    Zhang, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S491 - S491
  • [28] A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
    Benoit You
    Anthony Brade
    Joao M. Magalhaes
    Lillian L. Siu
    Amit Oza
    Sonya Lovell
    Lisa Wang
    David W. Hedley
    Leonardo V. Nicacio
    Eric X. Chen
    Investigational New Drugs, 2011, 29 : 996 - 1003
  • [29] A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
    You, Benoit
    Brade, Anthony
    Magalhaes, Joao M.
    Siu, Lillian L.
    Oza, Amit
    Lovell, Sonya
    Wang, Lisa
    Hedley, David W.
    Nicacio, Leonardo V.
    Chen, Eric X.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 996 - 1003
  • [30] FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study
    Li, Qiao
    Wang, Xian
    Cheng, Ying
    Liu, Yunjiang
    Chang, Jianhua
    Wang, Zhuo
    Wu, Chunjiao
    Wang, Mingxia
    Hui, Ai-Min
    Wu, Zhuli
    Jin, Yongli
    Huang, Xin
    Zhong, Liping
    Diao, Lei
    Zhao, Han
    Xu, Binghe
    CANCER RESEARCH, 2023, 83 (05)
12345